FAYE M JOHNSON to Disease Progression
This is a "connection" page, showing publications FAYE M JOHNSON has written about Disease Progression.
Connection Strength
0.155
-
Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers? Expert Opin Investig Drugs. 2017 Feb; 26(2):207-217.
Score: 0.062
-
EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila). 2009 Dec; 2(12):1039-49.
Score: 0.038
-
Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clin Cancer Res. 2020 07 01; 26(13):3211-3219.
Score: 0.020
-
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):67-73.
Score: 0.018
-
Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer. 2018 05 15; 124(10):2169-2173.
Score: 0.017